Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Chimeric antigen receptor (CAR) T cell therapy is effective against blood cancers but faces challenges with solid tumors.
• Oncolytic viruses (OVs) are emerging as a promising cancer treatment strategy.
• The tumor microenvironment often hinders CAR T cell efficacy.

Purpose of the Study:

• To explore the synergistic potential of combining CAR T cells with oncolytic viruses (OVs) for solid tumor treatment.
• To evaluate how OVs can enhance CAR T cell function within the tumor microenvironment.

Main Methods:

• Preclinical studies investigating the combined effects of CAR T cells and OVs.
• Analysis of CAR T cell trafficking, antitumor activity, and elimination of antigen-negative tumor cells in combination therapy models.

Main Results:

• Preclinical data indicate that combining CAR T cells with OVs can improve CAR T cell trafficking and antitumor efficacy.
• This combination therapy demonstrated enhanced elimination of antigen-negative tumor cells.
• One clinical trial (NCT03740256) is currently investigating this combination.

Conclusions:

• CAR T cell and OV combination therapy holds significant preclinical promise for solid tumors.
• Clinical translation is limited by factors including antiviral immunity, administration route, cost, and safety concerns.
• Strategies to reduce production costs and enhance OV bioavailability are crucial for advancing this approach in clinical trials.